Evidence map›Paper›PMID 38651882›Full record

ArticleMicrobiology spectrum2024

Novel antimony-based antimicrobial drug targets membranes of Gram-positive and Gram-negative bacterial pathogens.

Tarosha Salpadoru, Kevin E Pinks, Jacob A Lieberman, Kaitlyn Cotton, Karen L Wozniak, Nikolay Gerasimchuk, Marianna A Patrauchan

Open access · goldAbstract read
In one paragraph

Article in Microbiology spectrum, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Tarosha SalpadoruDepartment of Microbiology and Molecular Genetics, Oklahoma State University, Stillwater, Oklahoma, USA.ORCID 0000-0002-3711-5501
Kevin E PinksDepartment of Chemistry and Biochemistry, Missouri State University, Springfield, Missouri, USA.
Jacob A LiebermanDepartment of Microbiology and Molecular Genetics, Oklahoma State University, Stillwater, Oklahoma, USA.
Kaitlyn CottonDepartment of Microbiology and Molecular Genetics, Oklahoma State University, Stillwater, Oklahoma, USA.
Karen L WozniakDepartment of Microbiology and Molecular Genetics, Oklahoma State University, Stillwater, Oklahoma, USA.
Nikolay GerasimchukDepartment of Chemistry and Biochemistry, Missouri State University, Springfield, Missouri, USA.
Marianna A PatrauchanDepartment of Microbiology and Molecular Genetics, Oklahoma State University, Stillwater, Oklahoma, USA.ORCID 0000-0002-0495-3867
Oklahoma State University · USMissouri State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antimicrobial resistance (AMR) poses a significant worldwide public health crisis that continues to threaten our ability to successfully treat bacterial infections. With the decline in effectiveness of conventional antimicrobial therapies and the lack of new antibiotic pipelines, there is a renewed interest in exploring the potential of metal-based antimicrobial compounds. Antimony-based compounds with a long history of use in medicine have re-emerged as potential antimicrobial agents. We previously synthesized a series of novel organoantimony(V) compounds complexed with cyanoximates with a strong potential of antimicrobial activity against several AMR bacterial and fungal pathogens. Here, five selected compounds were studied for their antibacterial efficacy against three important bacterial pathogens: IMPORTANCE: Antibiotic resistance presents a critical global public health crisis that threatens our ability to combat bacterial infections. In light of the declining efficacy of traditional antibiotics, the use of alternative solutions, such as metal-based antimicrobial compounds, has gained renewed interest. Based on the previously synthesized innovative organoantimony(V) compounds, we selected and further characterized the antibacterial efficacy of five of them against three important Gram-positive and Gram-negative bacterial pathogens. Among these compounds, SbPh

Indexed as

Anti-Bacterial AgentsAntimonyGram-Negative BacteriaMicrobial Sensitivity TestsCell MembraneEscherichia coliGram-Positive BacteriaHumansPseudomonas aeruginosaStaphylococcus aureusAnti-Bacterial AgentsAntimonybroad spectrumcombination therapycytotoxicity

Identifiers

PMID38651882
PMCPMC11237720
OpenAlexW4395037772

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.